1型人类免疫缺陷病毒重组gp120疫苗诱导的唾液结合抗体。美国国立过敏与传染病研究所艾滋病疫苗评估小组。
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.
作者信息
Gorse G J, Yang E Y, Belshe R B, Berman P W
机构信息
Department of Internal Medicine, Saint Louis University School of Medicine, Missouri, USA.
出版信息
Clin Diagn Lab Immunol. 1996 Nov;3(6):769-73. doi: 10.1128/cdli.3.6.769-773.1996.
Abstract
Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.
摘要
在一项评估单独肌内注射HIV-1MN重组gp120（rgp120）疫苗或联合HIV-1IIIB rgp120疫苗的临床试验中，对健康的、未感染HIV-1的志愿者中由候选1型人类免疫缺陷病毒（HIV-1）疫苗诱导产生的唾液结合抗体进行了评估。这两种rgp120疫苗在全唾液和血清中诱导产生了包膜糖蛋白特异性免疫球蛋白G（IgG）和IgA抗体。
相似文献
1
Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group.1型人类免疫缺陷病毒重组gp120疫苗诱导的唾液结合抗体。美国国立过敏与传染病研究所艾滋病疫苗评估小组。
Clin Diagn Lab Immunol. 1996 Nov;3(6):769-73. doi: 10.1128/cdli.3.6.769-773.1996.
2
Antibody to native human immunodeficiency virus type 1 envelope glycoproteins induced by IIIB and MN recombinant gp120 vaccines. The NIAID AIDS Vaccine Evaluation Group.由IIIB和MN重组gp120疫苗诱导产生的针对天然人类免疫缺陷病毒1型包膜糖蛋白的抗体。美国国立过敏与传染病研究所艾滋病疫苗评估小组。
Clin Diagn Lab Immunol. 1996 Jul;3(4):378-86. doi: 10.1128/cdli.3.4.378-386.1996.
3
HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.由HIV-1MN重组糖蛋白120疫苗增强的HIV-1MN重组糖蛋白160疫苗诱导的细胞免疫和体液免疫。美国国立过敏与传染病研究所艾滋病疫苗评估小组。
AIDS Res Hum Retroviruses. 1999 Jan 20;15(2):115-32. doi: 10.1089/088922299311547.
4
MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.MN和IIIB重组糖蛋白120疫苗诱导产生针对1型人类免疫缺陷病毒原始分离株天然包膜糖蛋白的结合抗体。美国国立过敏和传染病研究所艾滋病疫苗评估小组。
AIDS Res Hum Retroviruses. 1999 Jul 1;15(10):921-30. doi: 10.1089/088922299310638.
5
Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.使用添加皂苷佐剂（QS-21）的亚单位疫苗制剂诱导针对HIV-1 gp120的交叉反应性细胞毒性T淋巴细胞反应。
Vaccine. 1997 Jun;15(9):1001-7. doi: 10.1016/s0264-410x(96)00293-9.
6
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.金丝雀痘病毒表达HIV-1MN gp120、HIV-1SF2重组gp120或两种疫苗在血清阴性成年人中诱导的对1型人类免疫缺陷病毒（HIV）的免疫反应。美国国立过敏和传染病研究所艾滋病疫苗评估小组。
J Infect Dis. 1998 May;177(5):1230-46. doi: 10.1086/515288.
7
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.用来自HIV-1 MN株的重组gp120免疫的血清阴性志愿者体内针对HIV-1的中和抗体。美国国立过敏与传染病研究所艾滋病疫苗临床试验网络。
JAMA. 1994 Aug 10;272(6):475-80. doi: 10.1001/jama.272.6.475.
8
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.在未感染的HIV-1IIIB重组gp120亚单位疫苗接种者中诱导HIV-1中和抗体和抑制合胞体形成抗体
Lancet. 1993 Jul 10;342(8863):69-73. doi: 10.1016/0140-6736(93)91283-r.
9
HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.接种MF59/重组gp120疫苗的HIV暴露婴儿比接种同一疫苗的成人具有更高水平的抗V1V2 IgG反应。
J Virol. 2017 Dec 14;92(1). doi: 10.1128/JVI.01070-17. Print 2018 Jan 1.
10
HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.无法中和HIV-1原始分离株的HIV-1MN重组gp120疫苗血清，不会拮抗来自受感染个体的抗体的中和作用。
AIDS. 1994 Nov;8(11):1622-3. doi: 10.1097/00002030-199411000-00017.
引用本文的文献
1
Building and testing an effective HIV vaccine.构建并测试一种有效的HIV疫苗。
West J Med. 1999 Nov-Dec;171(5-6):363-5.
本文引用的文献
1
Clinical and epidemiologic features of primary HIV infection.原发性HIV感染的临床和流行病学特征。
Ann Intern Med. 1996 Aug 15;125(4):257-64. doi: 10.7326/0003-4819-125-4-199608150-00001.
2
Protection against vaginal SIV transmission with microencapsulated vaccine.微囊化疫苗预防阴道内猴免疫缺陷病毒传播
Science. 1993 May 28;260(5112):1323-7. doi: 10.1126/science.8493576.
3
Mucosal immunity, HIV transmission, and AIDS.黏膜免疫、HIV传播与艾滋病
Lab Invest. 1993 Feb;68(2):129-45.
4
Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients.HIV-1感染者和血清学阴性疫苗接种者的黏膜分泌物及血清中针对重组gp160的抗体。
AIDS Res Hum Retroviruses. 1993 Jul;9(7):627-32. doi: 10.1089/aid.1993.9.627.
5
Serum IgA-mediated neutralization of HIV type 1.血清免疫球蛋白A介导的1型人类免疫缺陷病毒中和作用
J Immunol. 1994 May 1;152(9):4642-8.
6
Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.在未感染的HIV-1IIIB重组gp120亚单位疫苗接种者中诱导HIV-1中和抗体和抑制合胞体形成抗体
Lancet. 1993 Jul 10;342(8863):69-73. doi: 10.1016/0140-6736(93)91283-r.
7
A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV.一项关于异性伴侣间人类免疫缺陷病毒传播的纵向研究。欧洲艾滋病毒异性传播研究小组。
N Engl J Med. 1994 Aug 11;331(6):341-6. doi: 10.1056/NEJM199408113310601.
8
Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals.HIV感染个体中IgA和IgG中和能力及对1型HIV gp120 V3环反应的对比
AIDS Res Hum Retroviruses. 1994 Jul;10(7):813-22. doi: 10.1089/aid.1994.10.813.
9
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.用来自HIV-1 MN株的重组gp120免疫的血清阴性志愿者体内针对HIV-1的中和抗体。美国国立过敏与传染病研究所艾滋病疫苗临床试验网络。
JAMA. 1994 Aug 10;272(6):475-80. doi: 10.1001/jama.272.6.475.
10
Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.重新评估黏膜免疫在人类免疫缺陷病毒（HIV）感染中的作用及相关疫苗的设计。
J Clin Immunol. 1994 Sep;14(5):259-72. doi: 10.1007/BF01540979.
Zotero 插件